Author:
Jinnouchi Hideaki,Yoshida Akira,Tsuyuno Hiromi,Iwamoto Kiyoko,Sugiyama Seigo,Hieshima Kunio,Kajiwara Keizo,Kurinami Noboru,Suzuki Tomoko,Jinnouchi Katsunori,Jinnouchi Tomio
Funder
Taisho Toyama Pharmaceutical Co Ltd
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference29 articles.
1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271-281. PMID:29496507. doi: 10.1016/j.diabres.2018.02.023.
2. Introduction: Standards of medical care in diabetes-2019;American Diabetes Association;Diabetes Care,2019
3. Japan Diabetes Clinical Data Management Study Group. Basic accumulated data 2018. http://jddm.jp/data/index-2018/. Accessed January 27, 2020. (in Japanese)
4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
5. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH;Shiba;Sci Rep,2018
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献